Q-omics provides the consensus-scored PEX11B profile across patient tissues and cancer cell-line models. PEX11B expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PEX11B is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, PEX11B RNA expression shows 19,431 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LIHC as cancer lineages where PEX11B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PEX11B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PEX11B survival associations across molecular data types. PEX11B RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PEX11B RNA expression–survival associations across cancer types. High PEX11B expression shows unfavorable associations in ACC, LIHC and LAML, but favorable associations in KIRC, LUSC and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PEX11B RNA expression.
This table summarizes PEX11B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 8. The strongest signals are observed in LIHC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PEX11B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PEX11B shows lower tumor expression in KICH and higher tumor expression in LIHC, LUAD, STAD, BRCA and CHOL. The LIHC box plot shows higher PEX11B RNA expression in tumor versus normal tissue (log2 FC = +1.042, t-test p < 0.001).
This table shows molecular features associated with PEX11B in patient tissues and cancer cell lines. In patient samples, PEX11B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PEX11B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
